Investigation of smoking on the antiplatelet response to clopidogrel: Unravelling the smoker’s paradox

• Published in: Pathology, research and practice Vol. 257; p. 155290
• Main Authors: Plakogiannis, Frank A., Weidmann, Jakob, Fraser, Blake, Kwong, Justin, Asi, Diana, Kumar, Pratham, Baldock, Madeleine, Naamo, Jasmine, Baluja, Ruhani, Catanzariti, Rachelle, Yeung, Stewart, Pont, Lisa, Williams, Kylie, De Rubis, Gabriele, Dua, Kamal, Bukhari, Nadeem Irfan
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01.05.2024
• Subjects: Acute Coronary Syndrome; Antiplatelet; Clopidogrel; Clopidogrel - therapeutic use; Cytochrome P-450 CYP1A2 - genetics; Cytochrome P-450 CYP1A2 - metabolism; Cytochrome P-450 CYP2C19 - genetics; Cytochrome P-450 CYP2C19 - metabolism; Humans; P2Y12 Inhibitors; Platelet Aggregation Inhibitors - pharmacology; Platelet Aggregation Inhibitors - therapeutic use; Smokers; Smoker’s Paradox; Smoking; Smoking - adverse effects; INH; Optimal Strategy to Medically Manage; PRI; TRILOGY ACS; MACCE; OPR; PRU; CHARISMA; DR-IPA; Smoker’s Paradox; CYP; MI; CKD; CURRENT-OASIS; PFT; Acute Coronary Syndrome; PRINCE; LOF; CAD; HOPR; Usage to Reduce Recurrent Events−Seventh; T2-DM; CVD; ACS; Antiplatelet; P2Y12 Inhibitors; C-IPA; PAHs; Clopidogrel; Smoking
• ISSN: 0344-0338; 1618-0631
• DOI: 10.1016/j.prp.2024.155290

The intricate relationship between smoking and the effects of the antiplatelet drug clopidogrel has been termed the “smoker’s paradox”. This paradox details the enhanced efficacy of clopidogrel in smokers compared to non-smokers. This review begins with an exploration of the proposed mechanisms of the smoker's paradox, particularly drawing attention to the induction of cytochrome P450 (CYP) isoenzymes via tobacco smoke, specifically the enzymes CYP1A2 and CYP2C19. Moreover, an investigation of the effects of genetic variability on the smoker’s paradox was undertaken from both clinical and molecular perspectives, delving into the effects of ethnicity and genetic polymorphisms. The intriguing role of CYP1A2 genotypes and the response to clopidogrel in smoking and non-smoking populations was examined conferring insight into the individuality rather than universality of the smoker’s paradox. CYP1A2 induction is hypothesised to elucidate the potency of smoking in exerting a counteracting effect in those taking clopidogrel who possess CYP2C19 loss of function polymorphisms. Furthermore, we assess the comparative efficacies of clopidogrel and other antiplatelet agents, namely prasugrel and ticagrelor. Studies indicated that prasugrel and ticagrelor provided a more consistent effect and further reduced platelet reactivity compared to clopidogrel within both smoking and non-smoking populations. Personalised dosing was another focus of the review considering patient comorbidities, genetic makeup, and smoking status with the objective of improving the antiplatelet response of those taking clopidogrel. In summation, this review provides insight into multiple areas of research concerning clopidogrel and the smoker’s paradox taking into account proposed mechanisms, genetics, other antiplatelet agents, and personalised dosing. [Display omitted]